SYNNEX Corporation, a Fortune 500 corporation, is a leading business process services company, servicing re-sellers and original equipment manufacturers, or OEMs, in multiple regions around the world. The Company provides services in IT distribution, supply chain management, contract assembly and global business services.

• Promoted a wide range of products ranging from topical creams for fibromyalgia to prescription vitamins for the treatment of diabetic and peripheral neuropathy• Routinely call on specialty offices such as endocrinology, neurology, podiatry, orthopedist, OB/GYN, and internal medicine.

• Represent and promote Invokana (canagiflozin) and Invokamet (canagliflozin/metformin) for the treatment of T2DM as well as Xarelto (rivaroxaban) for the treatment of nonvalvular atrial fibrillation and treatment and prevention of deep vein thrombosis and pulmonary embolism• Launched Invokamet XR (canagiflozin/extended-release metformin) • Joined endocrinology specialty team as of January 1, 2017

• Finished FY’15 Q2 142% to Annualized Operation Profit in New Patient Total Pumps• Finished FY’ 15 Q2 ranked top 10% for FY’ 15 Q2 the first quarter of employment • Co-lead project for a comparative product analysis for the Minimed Connect and Dexcom G5 continuous glucose monitoring applications• Achieved sales goals by educating patients on the clinical value of insulin pump therapy coupled with an integrated continuous glucose monitor device • Educated districts on diabetic technology industry updates daily in meetings• Awarded Earl Bakken Medallion for excellence in customer service

• Acknowledged in a major study for determining pre-diabetic risk factors• Enhanced research skills by extracting and interpreting data of hundreds of medical records• Transposed print medical records to EMR (electronic medical records) database